Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - celecoxib; gelatin - capsule, hard - 100 milligram(s) - coxibs; celecoxib

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; iron oxide yellow; silicon dioxide; iron oxide red; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: silicon dioxide; iron oxide yellow; iron oxide red; titanium dioxide; magnesium stearate; sodium starch glycollate type a; gelatin; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: gelatin; sodium starch glycollate type a; iron oxide yellow; silicon dioxide; magnesium stearate; titanium dioxide; iron oxide red; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 66.8 mg (equivalent: sunitinib, qty 50 mg) - capsule - excipient ingredients: sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; shellac; povidone; magnesium stearate; sodium hydroxide; gelatin; iron oxide black; iron oxide red; propylene glycol; mannitol; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: sodium hydroxide; titanium dioxide; mannitol; shellac; sodium lauryl sulfate; iron oxide red; propylene glycol; povidone; croscarmellose sodium; magnesium stearate; gelatin; iron oxide black; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 16.7 mg (equivalent: sunitinib, qty 12.5 mg) - capsule - excipient ingredients: sodium hydroxide; propylene glycol; shellac; sodium lauryl sulfate; iron oxide red; mannitol; magnesium stearate; titanium dioxide; povidone; gelatin; croscarmellose sodium - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - crizotinib, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; calcium hydrogen phosphate; iron oxide red; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - crizotinib, quantity: 200 mg - capsule, hard - excipient ingredients: titanium dioxide; gelatin; calcium hydrogen phosphate; colloidal anhydrous silica; microcrystalline cellulose; iron oxide red; magnesium stearate; sodium starch glycollate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - isavuconazonium sulfate - capsule - 100mg